KNOW YOUR TUMOR®



Powerful Knowledge. Personalized Treatment.®

There is no roadmap for treating pancreatic cancer. We are learning more about the disease, and new information is discovered every day. What has become clear is that pancreatic cancer is heterogeneous and should be treated based on the biology of a patient's tumor. Our Know Your Tumor service gives you direct access to information about the molecular profile of your patient's tumor.

MORE TREATMENT OPTIONS

Our Know Your Tumor service, provided in partnership with Perthera, is an IRB-approved protocol that provides you with a molecular profiling report of your patient's tumor. The report includes treatment options, which are determined after report findings are interpreted by an expert panel, providing valuable insight to support your treatment decisions.

Treatment options are personalized to your patient and may include:

- Targeted therapy, which avoids the toxicity of multi-agent chemotherapy
- Appropriate clinical trials, including molecularly targeted solid tumor trials
- Off-label treatments that may be particularly effective for your patient's specific tumor mutations
- Standard of care treatments

"When I refer patients to Know Your Tumor, I feel like we join an all-star team with great resources dedicated to helping our particular patient."

 Dr. Andrew E. Hendifar, medical oncology lead for the gastrointestinal disease research group at Cedars-Sinai Medical Center

More than 200 physicians – from institutions such as Cedars-Sinai Medical Center, Johns Hopkins, Virginia Mason Medical Center and Memorial Sloan-Kettering – have received Know Your Tumor reports for their patients.

REPORT PROCESS

The Pancreatic Cancer Action Network partners with a comprehensive precision medicine company, Perthera, that combines advanced molecular diagnostic testing, including genomic profiling and proteomic analysis, through CLIA-Certified laboratories. Using a proprietary Expert Oncology platform, patient history analysis, molecular profile of the patient's tumor and the input of board-certified oncologists, the resulting report will help you identify the best treatment options for your patient. The service will:

- Provide you with the specific instructions for obtaining tumor tissue
- Coordinate the shipment of your patient's tissue from the hospital/medical center
- Send your patient's tumor tissue to multiple molecular diagnostic companies for testing
- Integrate the results and provide you with a report, interpreted by pancreatic cancer experts, which includes personalized treatment options for your patient

ACCELERATING PANCREATIC CANCER RESEARCH

The Pancreatic Cancer Action Network has created the Patient Registry, an online global database, to look for patterns in treatments, side effect management and diagnostics that will lead to improved treatment options and patient outcomes. Patients and caregivers share their experiences and their Know Your Tumor reports in this registry, helping researchers learn more about the commonalities in the makeup of pancreatic tumors in order to focus their efforts on highly prevalent biomarkers.



KNOW YOUR TUMOR® FAQs FOR HEALTHCARE PROFESSIONALS



WHY SHOULD I USE MOLECULAR PROFILING FOR MY PATIENT?

There is no roadmap for treating pancreatic cancer. We are learning more about the disease, and new information is discovered every day. What is clear is that pancreatic cancer is heterogeneous and should be treated based on the biology of a patient's tumor.

Our Know Your Tumor service, provided in partnership with Perthera, is an IRB-approved protocol that provides you with a molecular profiling report of your patient's tumor. The report includes treatment options, which are determined after report findings are interpreted by an expert panel, providing valuable insight to support your treatment decisions.

Treatment options are personalized to your patient and may include:

- Targeted therapy, which avoids the toxicity of multi-agent chemotherapy.
- Appropriate clinical trials, including molecularly targeted solid tumor trials.
- Off-label treatments that may be particularly effective for your patient's specific tumor mutations.
- Standard of care treatments that are compared against biomarker-based treatments.

Information provided in the reports can help provide a better understanding of the disease and treatment options, and findings contribute to future research and development of new therapies for pancreatic cancer.

HOW DOES THE KNOW YOUR TUMOR SERVICE WORK?

The Pancreatic Cancer Action Network partners with a comprehensive precision medicine company, Perthera, that combines advanced molecular diagnostic testing, including genomic profiling and proteomic analysis along with optional germline testing, through CLIA-Certified laboratories. Perthera uses a proprietary Expert Oncology platform, patient history analysis and the input of board-certified oncologists to help you identify the best treatment options for your patient's unique cancer.

Perthera will:

- Provide you with the specific instructions for obtaining tumor tissue through:
 - a biopsy of a primary or metastatic tumor (for unresectable tumors), or
 - use of a surgical specimen from a recent (less than 12 months) pancreatic tumor resection.
- Coordinate the shipment of your patient's tissue from the hospital/medical center to Perthera.
- Send your patient's tumor tissue to multiple molecular diagnostic companies for testing and have the results interpreted by pancreatic cancer experts.
- Integrate the results and expert interpretation to provide you with a report that has personalized treatment options for your patient.

While there is no guarantee that the biomarkers identified in the multiplex molecular testing process will be actionable for guiding treatment, this service will give you confidence about your patient's diagnosis and available treatment options.

WHO IS ELIGIBLE TO PARTICIPATE?

The criteria listed below will help you decide which of your patients are best suited for the Know Your Tumor service:

- Patient has diagnosis of pancreatic malignancy
- Patient has no sign of progression or impending need to change treatment
 - Completion and delivery of the report takes approximately 30 45 days from receipt of tissue
- Tumor tissue is obtainable
 - Newly obtained core biopsy, 4 6 cores with 18 20 gauge needle preferred
 - From accessible metastatic site
 - From primary site, if biopsy acquisition is deemed an acceptable risk

- Surgical specimen (surgical resection must have occurred no more than 12 months prior to enrollment, with no other source of tissue available)
- Patient resides in the United States/Canada and is not imprisoned
- Patient or close caregiver is able to read and speak English or Spanish

HOW LONG DOES THE PROCESS TAKE?

It will take approximately 30-45 days from receipt of tissue for the Perthera report to be completed and delivered to you and your patient. Additionally, if a tissue sample is not already available, the time needed to obtain a tissue sample should be factored in when understanding the amount of time that will lapse before you receive a patient's report. You may find it appropriate for your patient to start a new line of treatment while waiting for completion of the report. You and your patient should begin the Know Your Tumor process as soon as possible to ensure the report is available to help inform the patient's next line treatment.

WHAT WILL KNOW YOUR TUMOR COST MY PATIENT?

The Pancreatic Cancer Action Network covers the full cost of Perthera's services for patients enrolled in Know Your Tumor. This includes:

- Working with doctors and patients to coordinate procedures, such as a biopsy, to obtain tumor tissue for testing.
- Sending the tissue to the laboratories for testing.
- Having a panel of pancreatic cancer experts review the results.
- Providing the patient and his/her doctor with a report that gives information about the unique characteristics of the patient's tumor and a list of treatment options for the doctor and patient to consider.

Medical procedures – including biopsies – and molecular testing will be billed to the patient's insurance. The patient will be responsible for any co-pay, co-insurance or insurance deductible associated with a procedure to obtain tumor tissue and for the molecular testing. Perthera can help your office bill insurance for the procedure so that most insurance providers will cover it.

Perthera's patient coordinator can provide patients with information on applying for financial assistance programs available through the molecular testing laboratories used to help reduce or eliminate the bill for molecular testing.

WHAT IF THE TREATMENTS ON THE REPORT ARE NOT COVERED BY MY PATIENT'S INSURANCE?

Should insurance coverage issues arise, our Know Your Tumor CareLine (in partnership with the Patient Advocate Foundation) may be able to help.

WHAT IS MY ROLE DURING THIS PROCESS?

You play an important role in this process. Perthera will be in contact to collect order forms from you and arrange the transfer of tissue samples. As the process can take more than a month, it is important to get each step of the process underway as quickly as possible so that you will have a completed report ready to help you make a decision on the next line of treatment when needed. In order to receive your patient's report as quickly as possible and ensure program completion, it is important for your office and your patient to respond to any communication from the Pancreatic Cancer Action Network and Perthera in a timely manner.

HOW DO I ENROLL MY PATIENTS?

Enrollment in Know Your Tumor is a two-part process.

- 1. You complete an order form giving permission for patient enrollment and for Perthera to collect tissue and order testing.
- 2. The patient will sign an informed consent with Perthera to participate in this IRB-approved protocol. The patient will then be connected to the Pancreatic Cancer Action Network to complete enrollment.

